Acrivon Therapeutics, Inc. Common Stock – NASDAQ:ACRV

Add to watchlist

$1.34

-4.58

-77.37%

Market closed

Open in about 15 hours

-20.54%

month

-20.54%

quarter

+18.16%

year

Market Cap	202.07M
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	-2.88

Revenue	N/A
EBITDA	-69.87M
Income	-64.11M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Acrivon Therapeutics, Inc. Common Stock Stock Forecast

M Q Y

Last Year

$24.33

Potential upside: 1716.46%

Analysts Price target
Financials & Ratios estimates

Acrivon Therapeutics, Inc. Common Stock (NASDAQ:ACRV): Profit margin
Jun 2023	0	-13.91M
Sep 2023	0	-14.46M
Dec 2023	1.88M	-19.25M	-1021.87%
Mar 2024	0	-16.48M

Acrivon Therapeutics, Inc. Common Stock (NASDAQ:ACRV): Earnings per share (EPS)
2024-03-28	-0.72	-0.86
2024-05-14	-0.89	-0.73

Acrivon Therapeutics, Inc. Common Stock (NASDAQ:ACRV): Debt to assets
Jun 2023	160049000	10.86M	6.79%
Sep 2023	151092000	12.94M	8.57%
Dec 2023	138265000	17.07M	12.35%
Mar 2024	120521000	12.54M	10.41%

Acrivon Therapeutics, Inc. Common Stock (NASDAQ:ACRV): Cash Flow
Jun 2023	-9.11M	19.33M	379K
Sep 2023	-9.80M	1.51M	78K
Dec 2023	-12.36M	20.53M	-2.01M
Mar 2024	-17.08M	5.85M	-172K

Acrivon Therapeutics, Inc. Common Stock alternative data

Acrivon Therapeutics, Inc. Common Stock
Employees

Acrivon Therapeutics, Inc. Common Stock (NASDAQ:ACRV): Employee count
Aug 2023	45
Sep 2023	50
Oct 2023	50
Nov 2023	50
Dec 2023	56
Jan 2024	56
Feb 2024	56
Mar 2024	58
Apr 2024	58
May 2024	58
Jun 2024	58
Jul 2024	58

Acrivon Therapeutics, Inc. Common Stock
Hedge Funds Holdings Q1 2023

91.37% -8.63%

of ACRV is owned by hedge funds

19 +1

hedge funds hold ACRV stock

3.76M -11.19M

shares is hold by hedge funds

ACRV hedge funds holdings changes

Acrivon Therapeutics, Inc. Common Stock
Insider Trading

Acrivon Therapeutics, Inc. Common Stock (NASDAQ:ACRV): Insider trades (number of shares)
Period	Buy	Sel
Jun 2023	0	7965
Apr 2024	2353000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	17 May 2024	DEVROE ERIC officer: Chief Operating Officer officer: Chief Operating Officer	Stock Option (Right to Buy)	10,000	$1.04	$10,400
Option	17 May 2024	DEVROE ERIC officer: Chief Operating Officer officer: Chief Operating Officer	Common Stock	10,000	$1.04	$10,400
Purchase	11 Apr 2024	PERCEPTIVE ADVISORS LLC 10 percent owner 10 percent owner	Common Stock	2,353,000	$8.5	$20,000,500
Sale	26 Jun 2023	CHIONE LTD 10 percent owner 10 percent owner	Common Stock	16	$12.93	$207
Option	16 Jun 2023	HOLM-JORGENSEN RASMUS officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	9,500	$3.63	$34,485
Option	16 Jun 2023	HOLM-JORGENSEN RASMUS officer: Chief Financial Officer officer: Chief Financial Officer	Stock Option (Right to Buy)	9,500	$3.63	$34,485
Sale	15 Jun 2023	CHIONE LTD 10 percent owner 10 percent owner	Common Stock	2,056	$12.14	$24,960
Sale	14 Jun 2023	CHIONE LTD 10 percent owner 10 percent owner	Common Stock	893	$12.13	$10,832
Sale	13 Jun 2023	CHIONE LTD 10 percent owner 10 percent owner	Common Stock	3,000	$12.3	$36,900
Sale	12 Jun 2023	CHIONE LTD 10 percent owner 10 percent owner	Common Stock	2,000	$12.34	$24,680

ACRV insider trading transactions

Acrivon Therapeutics, Inc. Common Stock
Latest News

Thursday, 12 December 2024
15:25	Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis	seekingalpha.com
Wednesday, 16 October 2024
16:00	Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Friday, 11 October 2024
08:00	Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity	globenewswire.com
Wednesday, 18 September 2024
10:11	Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects	seekingalpha.com
Saturday, 14 September 2024
03:10	Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis	globenewswire.com
Thursday, 15 August 2024
10:41	Are Medical Stocks Lagging Acrivon Therapeutics, Inc. (ACRV) This Year?	zacks.com
Friday, 21 June 2024
10:40	Is Acrivon Therapeutics, Inc. (ACRV) Stock Outpacing Its Medical Peers This Year?	zacks.com
Thursday, 13 June 2024
14:00	Acrivon Therapeutics: Can You Win In Clinical Trials With Selection Bias?	seekingalpha.com
Wednesday, 5 June 2024
10:40	Is Acrivon Therapeutics, Inc. (ACRV) Outperforming Other Medical Stocks This Year?	zacks.com
Wednesday, 29 May 2024
08:00	Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference	globenewswire.com
Tuesday, 28 May 2024
10:51	Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock	zacks.com
Friday, 24 May 2024
10:02	5 Small Drug Stocks to Buy From a Recovering Industry	zacks.com
Monday, 20 May 2024
10:46	Has Acrivon Therapeutics, Inc. (ACRV) Outpaced Other Medical Stocks This Year?	zacks.com
Tuesday, 14 May 2024
08:00	Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights	globenewswire.com
Friday, 10 May 2024
09:51	Is a Surprise Coming for Acrivon Therapeutics (ACRV) This Earnings Season?	Zacks Investment Research
Wednesday, 24 April 2024
19:16	Acrivon Therapeutics' shares climb 14% on plans to present cancer-test data	Market Watch
Sunday, 21 April 2024
08:45	Buffett Grabs More of This Stock, Plus Other Notable Insider Buying	24/7 Wall Street
Tuesday, 9 April 2024
10:32	ACRV Stock Jumps 55% as Acrivon Therapeutics Gets $130 Million Boost	InvestorPlace
Wednesday, 3 April 2024
03:07	What To Buy After You Sell The Russell 2000	Seeking Alpha
Tuesday, 5 March 2024
16:30	Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316	GlobeNewsWire
Tuesday, 6 February 2024
08:00	Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	GlobeNewsWire
Tuesday, 21 November 2023
08:00	Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference	GlobeNewsWire
Wednesday, 30 August 2023
08:00	Acrivon Therapeutics to Participate in Two Investor Conferences in September	GlobeNewsWire
Thursday, 29 June 2023
16:49	7 Up-and-Coming Stocks to Buy for the Next Decade	InvestorPlace
Friday, 2 June 2023
08:00	Acrivon Therapeutics to Present at the Jefferies Healthcare Conference	GlobeNewsWire
Tuesday, 25 April 2023
08:00	Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference	GlobeNewsWire
Tuesday, 18 April 2023
08:00	Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference	GlobeNewsWire
Sunday, 26 March 2023
09:53	Acrivon: Precision-Testing Your Trial Patients Before Enrolment	Seeking Alpha
Monday, 6 March 2023
08:00	Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference	GlobeNewsWire

Ideas & Opinions

Seeking Alpha 12 Dec 2024

Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis
Seeking Alpha 13 Jun 2024

Acrivon Therapeutics: Can You Win In Clinical Trials With Selection Bias?
Seeking Alpha 3 Apr 2024

What To Buy After You Sell The Russell 2000
Seeking Alpha 26 Mar 2023

Acrivon: Precision-Testing Your Trial Patients Before Enrolment

Frequently Asked Questions (FAQ)

What's the price of Acrivon Therapeutics, Inc. Common Stock stock today?

One share of Acrivon Therapeutics, Inc. Common Stock stock can currently be purchased for approximately $1.34.
When is Acrivon Therapeutics, Inc. Common Stock's next earnings date?

Unfortunately, Acrivon Therapeutics, Inc. Common Stock's (ACRV) next earnings date is currently unknown.
Does Acrivon Therapeutics, Inc. Common Stock pay dividends?

No, Acrivon Therapeutics, Inc. Common Stock does not pay dividends.
How much money does Acrivon Therapeutics, Inc. Common Stock make?

Acrivon Therapeutics, Inc. Common Stock has a market capitalization of 202.07M. Acrivon Therapeutics, Inc. Common Stock made a loss 60.39M US dollars in net income (profit) last year or -$0.73 on an earnings per share basis.
What is Acrivon Therapeutics, Inc. Common Stock's stock symbol?

Acrivon Therapeutics, Inc. Common Stock is traded on the NASDAQ under the ticker symbol "ACRV".
What is Acrivon Therapeutics, Inc. Common Stock's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Acrivon Therapeutics, Inc. Common Stock?

Shares of Acrivon Therapeutics, Inc. Common Stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does Acrivon Therapeutics, Inc. Common Stock have?

As Jul 2024, Acrivon Therapeutics, Inc. Common Stock employs 58 workers.
When Acrivon Therapeutics, Inc. Common Stock went public?

Acrivon Therapeutics, Inc. Common Stock is publicly traded company for more then 2 years since IPO on 15 Nov 2022.
What is Acrivon Therapeutics, Inc. Common Stock's official website?

The official website for Acrivon Therapeutics, Inc. Common Stock is acrivon.com.
Where are Acrivon Therapeutics, Inc. Common Stock's headquarters?

Acrivon Therapeutics, Inc. Common Stock is headquartered at 480 Arsenal Way, Watertown, MA.
How can i contact Acrivon Therapeutics, Inc. Common Stock?

Acrivon Therapeutics, Inc. Common Stock's mailing address is 480 Arsenal Way, Watertown, MA and company can be reached via phone at +61 72078979.
What is Acrivon Therapeutics, Inc. Common Stock stock forecast & price target?

Based on 2 Wall Street analysts` predicted price targets for Acrivon Therapeutics, Inc. Common Stock in the last 12 months, the avarage price target is $24.33. The average price target represents a 1716.46% change from the last price of $1.34.

Acrivon Therapeutics, Inc. Common Stock

acrivon.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

+61 72078979

480 Arsenal Way
Watertown, MA 02472

CIK: 0001781174
ISIN: US0048901096
CUSIP: 004890109